Method for protecting normal cells from cytotoxicity of chemotherapeutic agents
US6767926B1 · kind B1 · utility
14Cited by
9References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 11, 2000 |
| Grant date | Jul 27, 2004 |
| Priority date | — |
| Expiry date | Oct 11, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/35
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Pre-treatment with &agr;,&bgr; unsaturated aryl sulfones protects normal cells from the cytotoxic side effects of two classes of anticancer chemotherapeutics. Administration of a cytoprotective sulfone compound to a patient prior to anticancer chemotherapy with a mitotic phase cell cycle inhibitor or topoisomerase inhibitor reduces or eliminates the cytotoxic side effects of the anticancer agent on normal cells. The cytoprotective effect of the &agr;,&bgr; unsaturated aryl sulfone allows the clinician to safely increasing the dosage of the anticancer chemotherapeutic.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.